Purdue Pharma forms patent agreement with Acura, Egalet
According to the agreement, the three companies will exchange important regulatory rights and patent information. This will allow them to create and market many different opioid pain medicines that contain properties to deter users from abusing the opioids.
The U.S. continues to experience an ongoing abuse and misuse of prescription opioids that are meant to benefit patients who have serious medical needs. For over 10 years, pharmaceutical companies have used abuse-deterrent properties (OADPs) inside of opioids to prevent addiction to the medications.
Most recently, the U.S. Food and Drug Administration (FDA), the White House and the Drug Enforcement Administration (DEA) have encouraged researchers to develop new innovations to address the ongoing opioid addiction epidemic. Current OADPs and new developments are meant to continue benefitting patients with serious medical concerns, as well as to stop the abuse and manipulation of the drugs.
“This agreement reflects the commitment of Purdue Pharma to seek solutions that will enhance collaboration in the fight against prescription drug abuse,” Philip Strassburger, senior vice president of General Counsel, said. “It serves an important public health purpose to move the innovation in abuse-deterrent technologies forward.”
Organizations in this story
Purdue Pharma L.P 201 Tresser Blvd Stamford, CT 06901